Tumor News and Research

RSS

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Sorrento Therapeutics, Inc. and NantBioScience, Inc., a majority owned subsidiary of NantWorks, LLC, announced today that they have established a joint venture to focus on the development of 'first-in-class' small molecules against targets that have eluded the pharmaceutical industry to date and which may address important drivers of cancer growth including cancer stem cells.

9 Jul 2015

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Results published today in The New England Journal of Medicine from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared psoriasis or minimal psoriasis at week 16, the study's primary endpoint.

9 Jul 2015

Defects in mitochondria play key role in transition of normal cells to cancerous cells

Cancer cells defy the rules by which normal cells abide. They can divide without cease, invade distant tissues and consume glucose at abnormal rates.

9 Jul 2015

Computer model shows how cancerous tumors manipulate blood-vessel growth for their own benefit

Rice University researchers have built a simulation to show how cancerous tumors manipulate blood-vessel growth for their own benefit.

9 Jul 2015

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig Cancer Research and the Cancer Research Institute have launched clinical trials evaluating an immunotherapy for the treatment of the brain cancer glioblastoma multiforme (GBM), and a combination of immunotherapies for a variety of solid tumors.

8 Jul 2015

Scientists elucidate which mechanisms block natural killer cells and how this could be lifted

Natural killer cells of the immune system can fend off malignant lymphoma cells and thus are considered a promising therapeutic approach. However, in the direct vicinity of the tumor they lose their effect.

8 Jul 2015

Study aims to determine utility of Trovagene's PCM technology for predicting response to cancer immunotherapy

Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced the launch of a study that aims to determine utility of the Company's Precision Cancer Monitoring (PCM) technology for predicting response to treatment in advanced melanoma patients receiving one or a combination of the novel immunotherapy agents Yervoy (ipilumumab), a CTLA-4 inhibitor, and Opdivo (nivolumab), a PD-1 inhibitor.

8 Jul 2015

Researchers develop novel technique to generate activated T cells to tackle advanced melanoma

T cells from patients with melanoma can trigger a protective immune response against the disease according to a new study out of University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine.

8 Jul 2015

UC researcher awarded NCI grant to study effect of MED1 protein on HER2-positive breast cancer

Xiaoting Zhang, PhD, associate professor in the Department of Cancer Biology at the University of Cincinnati College of Medicine, has received a $1.8 million, five-year, R01 award (R01CA197865) from the National Cancer Institute to continue breast cancer research focusing on the function of the protein MED1 on HER2-positive breast cancer.

8 Jul 2015

Aspirin may inhibit the growth of mesothelioma, shows study

Aspirin may inhibit the growth of mesothelioma, an aggressive and deadly asbestos-related cancer, University of Hawai'i Cancer Center researchers have found.

7 Jul 2015

City of Hope researchers to use patients' own modified T cells to treat advanced brain tumors

Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine's biggest challenges: brain cancer. This month, they will launch a clinical trial using patients' own modified T cells to fight advanced brain tumors.

7 Jul 2015

LSD1 enzyme turns off genes needed to maintain cancer stem cell properties in glioblastoma

Cancer's ability to grow unchecked is often attributed to cancer stem cells, a small fraction of cancer cells that have the capacity to grow and multiply indefinitely. How cancer stem cells retain this property while the bulk of a tumor's cells do not remains largely unknown. Using human tumor samples and mouse models, researchers at University of California, San Diego School of Medicine and Moores Cancer Center discovered that cancer stem cell properties are determined by epigenetic changes -- chemical modifications cells use to control which genes are turned on or off.

7 Jul 2015

Study uncovers complicated role of simple protein in spread of osteosarcoma

The investigation of a simple protein has uncovered its uniquely complicated role in the spread of the childhood cancer, osteosarcoma. It turns out the protein, called ezrin, acts like an air traffic controller, coordinating multiple functions within a cancer cell and allowing it to endure stress conditions encountered during metastasis.

7 Jul 2015

Study could provide paradigm shift in treatment of age-related disease, cancer

Intermittent dosing with rapamycin selectively breaks the cascade of inflammatory events that follow cellular senescence, a phenomena in which cells cease to divide in response to DNA damaging agents, including many chemotherapies.

7 Jul 2015

New therapeutic alternative found for children suffering from Ewing's sarcoma

A research consortium made up of the Virgen del Rocio hospital in Seville, Sant Joan de Deu and the Bellvitge Biomedical Research Institute in Barcelona, has found a new therapeutic alternative for children who suffer from a malignant pediatric tumor bone and soft tissue called Ewing's sarcoma.

7 Jul 2015

Pazopanib improves survival in soft tissue sarcoma patients without impairment of health-related quality of life

Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.

7 Jul 2015

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies.

6 Jul 2015

Review article provides in depth survey of studies focusing on retinoblastoma protein's role in apoptosis

Retinoblastoma protein RB1, which is named after a form of pediatric tumor of the eye, is among the most common genetically regulated cellular proteins to malfunction in human cancer. RB1 was also the first tumor suppressor gene to be identified and its modes of inactivation in retinoblastoma tumors provided the basis for the ground-breaking two-hit hypothesis by the geneticist Alfred G. Knudson in the 70s, according to which cancer is due to the accumulation of multiple 'hits' or mutations in certain genes.

3 Jul 2015

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active.

2 Jul 2015

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells' resistance to paclitaxel.

2 Jul 2015

Tumor News and Research

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Defects in mitochondria play key role in transition of normal cells to cancerous cells

Computer model shows how cancerous tumors manipulate blood-vessel growth for their own benefit

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Scientists elucidate which mechanisms block natural killer cells and how this could be lifted

Study aims to determine utility of Trovagene's PCM technology for predicting response to cancer immunotherapy

Researchers develop novel technique to generate activated T cells to tackle advanced melanoma

UC researcher awarded NCI grant to study effect of MED1 protein on HER2-positive breast cancer

Aspirin may inhibit the growth of mesothelioma, shows study

City of Hope researchers to use patients' own modified T cells to treat advanced brain tumors

LSD1 enzyme turns off genes needed to maintain cancer stem cell properties in glioblastoma

Study uncovers complicated role of simple protein in spread of osteosarcoma

Study could provide paradigm shift in treatment of age-related disease, cancer

New therapeutic alternative found for children suffering from Ewing's sarcoma

Pazopanib improves survival in soft tissue sarcoma patients without impairment of health-related quality of life

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

Review article provides in depth survey of studies focusing on retinoblastoma protein's role in apoptosis

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News